EMP-01

atai Therapeutics, Inc. · Phase 2 active Small molecule

EMP-01 is an investigational drug developed by atai Therapeutics, Inc. for the treatment of social anxiety disorder. Currently in Phase 2, it has shown promising exploratory safety and efficacy results in a completed trial with 70 participants.

At a glance

Generic name	EMP-01
Sponsor	atai Therapeutics, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

EMP-01 CI brief — competitive landscape report
EMP-01 updates RSS · CI watch RSS
atai Therapeutics, Inc. portfolio CI